Stein, E. A., Sampietro, T., Santos, R., Harada-Shiba, M., Bruckert, E., Blom, D., … Raal, F. J. (2016). Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). Atherosclerosis, 252, e44–e44. https://doi.org/10.1016/j.atherosclerosis.2016.07.374

Stein, E. A., T. Sampietro, R. Santos, M. Harada-Shiba, E. Bruckert, D. Blom, G. K. Hovingh, et al. “Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig).” Atherosclerosis 252 (September 2016): e44–e44. https://doi.org/10.1016/j.atherosclerosis.2016.07.374.

Stein EA, Sampietro T, Santos R, Harada-Shiba M, Bruckert E, Blom D, et al. Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). Atherosclerosis. 2016 Sep;252:e44–e44.

Stein, E. A., et al. “Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig).” Atherosclerosis, vol. 252, Elsevier BV, Sept. 2016, pp. e44–e44. Crossref, doi:10.1016/j.atherosclerosis.2016.07.374.

Stein EA, Sampietro T, Santos R, Harada-Shiba M, Bruckert E, Blom D, Hovingh GK, Couture P, Blaha V, Farnier M, Descamps O, Soran H, Kasichayanula S, Gibbs J, Kurtz C, Tang L, Honarpour N, Wasserman SM, Raal FJ. Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). Atherosclerosis. Elsevier BV; 2016 Sep;252:e44–e44.